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The apoptotic program promotes
tissue remodeling and fibrosis
To the Editor: Havasi and Borkan1 discussed recent
observations that link apoptosis to cell deletion and loss of
organ function after acute kidney injury. Although the major
consequence of apoptosis is cell death, emerging evidence
suggests that apoptosis is involved in tissue remodeling and
ﬁbrogenesis.
The molecular machinery regulating the effector phase of
apoptosis favors the extracellular translocation of a highly
regulated set of mediators of importance in leukocyte
trafﬁcking and tissue remodeling. This molecular legacy
mounts a communication network with surrounding cells to
tissue repair in a paracrine manner, which is of importance in
the setting of kidney injury.2
Indeed, apoptotic cells release chemotactic factors,
including fractalkine, monocyte chemoattractant protein 1,
and lysophosphatidylcholine, to promote the recruitment
of macrophages and monocytes at the site of apoptosis.2
Apoptotic cells produce proﬁbrogenic cytokines, including
epidermal growth factor, and their engulfment by phagocytes
promotes transforming growth factor-b secretion. Caspase-3
activation in apoptotic endothelial cells triggers the export of
connective tissue growth factor, which in turn functions as a
necessary co-factor of myoﬁbroblast differentiation.3 Caspase-3
activation also leads to the externalization of cathepsin L,
which in turn cleaves the extracellular matrix component
perlecan generating a truncated C terminal fragment (LG3)
that activates prosurvival pathways in ﬁbroblasts and vascular
smooth muscle cells.4
In conclusion, apoptosis should be viewed not only as a
cell-deletion pathway but also as a biological process that
engages intercellular crosstalks of central importance in tissue
remodeling and repair.
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The Authors reply: In their letter, Pallet and He´bert1
astutely observe that renal cell injury including apoptosis
potentially aggravates renal fibrosis, inflammation, and
chronic organ injury. The specific messengers that precipitate
fibrosis and alterations in extracellular matrix proteins are
debated and include chemotactic factors, profibrogenic
cytokines such as epidermal growth factor and transforming
growth factor b, proinflammatory caspases, and cathepsin. In
addition, it is now accepted that acute kidney injury often
leaves subtle tubular and vascular defects associated with
renal fibrosis and increases the risk of end-stage renal
disease.2,3 In addition to the above ‘messengers of injury’,
recent evidence suggests that many cell types are capable of
releasing microvesicles containing both RNA and DNA that
induce signals in other cell types and even in distant tissues in
a paracrine/endocrine fashion.4 Although we focused on the
acute consequences of renal cell injury and apoptosis in our
review,5 Pallet and He´bert’s letter identifies a key research
area, namely, the biological relationship between acute and
chronic kidney injury and the propensity of acute renal
injury to precipitate damage in other organs. Given the
recent appreciation that acute injury begets chronic organ
disease,6 it is essential that we identify the profibrotic
messengers and their targets to interrupt an epidemic of
organ failure.
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Hydrogen sulfide increases after a
single hemodialysis session
To the Editor: Hydrogen sulﬁde, H2S, the third endogenous
gas with cardiovascular properties after nitric oxide and
carbon monoxide, is a newly recognized vasorelaxant, and
H2S deﬁciency is involved in the pathogenesis of hypertension
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and atherosclerosis.1 We demonstrated that in hemodialysis
patients, H2S levels are decreased through transcriptional
deregulation of genes encoding H2S-producing enzymes.
2
In fact, gene expression of cystathionine g-lyase (CSE), an
enzyme implicated in H2S formation, is downregulated in
these patients.2 We measured H2S levels before and after a
single standard 4-h hemodialysis session in 131 patients, in
two dialysis sessions separated by 1 month. Measurement
was performed by a slight modiﬁcation of our previously
published method.2 Basically, a 20-min incubation period was
added before deproteinization. Homocysteine is a main direct
H2S precursor in vivo, which functions through the catalytic
activity of either cystathionine b-synthase or CSE (see Perna
et al.3 for a review). Plasma total homocysteine was also
measured by using high-performance liquid chromatography
separation and ﬂuorescence detection.4
Both H2S and homocysteine data are expressed as mmol/l
concentrations. Results were analyzed with a paired two-
tailed t-test. Plasma H2S was signiﬁcantly increased after
dialysis (Figure 1 shows mean and s.e.). Homocysteine
levels were 40.90±2.087 mmol/l (s.e.) before dialysis and
21.83±1.142 mmol/l (s.e.) after dialysis, a highly signiﬁcant
decrease. No correlation was found between these two
parameters. However, the stoichiometry of homocysteine
metabolic conversion, yielding H2S, is encompassed in the
range 1:1–2:1, depending on the enzyme and/or the speciﬁc
reaction involved. After hemodialysis, the average reduction
in circulating homocysteine concentrations is 20 mmol/l,
whereas H2S increase approaches þ 10 mmol/l; this is in the
order of magnitude of what is expected for the reaction
stoichiometry and is highly consistent with the interpretation
of an improved homocysteine metabolism toward H2S
formation during dialysis.
Homocysteine is lowered by hemodialysis; however, this
can only in part be due to increased clearance through the
hemoﬁlter, as, with respect to other aminothiols, most
homocysteine is transported in circulation covalently bound
to serum albumin.5 Another mechanism (e.g., facilitated
metabolism as the result of removal of enzyme inhibition due
to a uremic toxin) is therefore likely to occur.
We conclude that hemodialysis is effective in acutely
reestablishing the altered H2S homeostasis in these patients.
We propose that plasma H2S elevation could be due to an
increase in its production secondary to removal of a uremic
toxin, inhibiting CSE, consistent with our previous ﬁndings,
and contributing to low blood pressure levels frequently seen
after dialysis.
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Figure 1 | Effect of hemodialysis on hydrogen sulfide (H2S)
plasma levels. *Po0.0001.
Kidney International (2011) 80, 1107–1109 1109
l e t t e r to the ed i to r
